Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study
Inotuzumab (InO)‐based frontline regimens have significantly improved the survival of older patients with Philadelphia‐negative (Ph–) B‐cell acute lymphoblastic leukemia (B‐ALL). Yet, outcome after relapse is not reported for this population.